Odynophagia: Is It Post-Transplant Lymphoproliferative Disorder? (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #PUB238; "He received basiliximab for induction and maintained on prednisone, tacrolimus (trough of 8-10 ng/mL), and mycophenolic acid (MPA)...Empiric treatment with fluconazole for esophageal candidiasis failed...He remains on prednisone, tacrolimus (trough of 5 ng/mL), and rituximab consolidation therapy...In our case, odynophagia was the unusual presenting feature that led to the diagnosis, underscoring the importance of considering PTLD in SOT recipients with atypical upper gastrointestinal symptoms. It also highlights the importance of early recognition of PTLD in EBV serostatus–mismatch recipients, who develop EBV seroconversion post-transplant."
Post-transplantation • B Cell Lymphoma • Candidiasis • Diffuse Large B Cell Lymphoma • Epstein-Barr Virus Infections • Genetic Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Nephrology • Non-Hodgkin's Lymphoma • Otorhinolaryngology • Polycystic Kidney Disease • Renal Disease • Solid Organ Transplantation • Transplantation • CD20
|
|
Krista Mecadon; Trevaughn Rawle Baptiste; Pooja V. Patel; Basma Omar Merhi
|